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nloaAntibodies targeting Ab42 are under intense scrutiny because of their therapeutic potential for Alzheimer’s
disease. To enable systematic searches, we present an “antibody scanning” strategy for the generation of a
panel of antibodies against Ab42. Each antibody in the panel is rationally designed to target a specific linear
epitope, with the selected epitopes scanning the Ab42 sequence. By screening in vitro the panel to identify the
specific microscopic steps in the Ab42 aggregation process influenced by each antibody, we identify two anti-
bodies that target specifically the primary and the secondary nucleation steps, which are key for the production
of Ab42 oligomers. These two antibodies act, respectively, to delay the onset of aggregation and to block the
proliferation of aggregates, and correspondingly reduce the toxicity in a Caenorhabditis elegans model over-
expressing Ab42. These results illustrate how the antibody scanning method described here can be used to
readily obtain very small antibody libraries with extensive coverage of the sequences of target proteins.ded
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 INTRODUCTION
The aggregation of the 42-residue form of the amyloid-b peptide
(Ab42) into amyloid fibrils is a key molecular process underlying
Alzheimer’s disease (AD) (1–5). Therefore inhibition of the aggrega-
tion process of Ab42 has been among the major therapeutic strate-
gies directed against AD (1–10). Nevertheless, compounds designed
for this purpose have yet to reach the clinic (2, 11). These failures are,
at least in part, due to the complexity of the aggregation behavior of
Ab42, which involves a series of tightly coupled microscopic steps
(12, 13). Because of this complexity, as recent studies on the kinetics
of aggregation have shown, the suppression of fibril formation can
have surprising outcomes, in some cases even increasing, rather than
decreasing, the concentration of potentially toxic oligomeric species
(6). It is, therefore, of critical importance for the development of ef-
fective therapies to design, in a rationalmanner, molecules capable of
acting selectively on the critical steps of formation of the toxic species
in the aggregation process (6).
Over the past decade, increasing evidence has implicated prefibrillar
oligomeric species, rather than mature amyloid fibrils, as the major
agents responsible for cellular toxicity in AD and similar pathologies
(14–19). Recently, major advances in understanding the molecular
mechanisms underlying the formation by Ab42 of such toxic species
have beenmade (13). In particular, it has been shown that, once a small
but critical concentration of aggregates has formed through the self-
assembly of Ab42 monomers as a result of primary nucleation events,
surface-catalyzed secondary nucleation becomes important because the
surfaces of existing fibrils can catalyze the generation of new oligomeric
species (13). These oligomers can then grow and convert into additional
fibrils, thus providing a positive feedback mechanism that results in
rapid aggregate proliferation (13). A consequence of this mechanism
is that compounds capable of selectively interfering with either the
primary nucleation or the surface-catalyzed secondary nucleation ofAb42 have the potential to suppress the formation of aggregated forms
of Ab42. Molecular chaperones (20, 21) and carefully selected small
molecules (22, 23) have been shown to be able to act in this manner.
Here, we extend this strategy to antibodies with an aim of using them
against AD by directly affecting different microscopic steps in Ab42 ag-
gregation. This goal is inspired by the view that antibodies, which can be
obtained with well-established methods such as immunization or phage
and associated display methods against a wide variety of targets (24–29),
can have wide applicability in diagnostics and therapeutics because of their
high target selectivity (30–34). In particular, a traditional and generally effec-
tive therapeutic approach of using antibodies is active immunotherapy,
which consists of boosting our natural immune defense by the administra-
tion of harmless versions of the pathogenic agents (35, 36). This approach,
which represents oneof themostpromising strategies against cancer (35,37),
is currently being explored for the treatment of AD, although with diffi-
culties inbalancing the immune responsewhilemaintaining efficacy (7–9).
Here, we adopt a different approach, as we use antibodies as compounds
that directly inhibit the aggregation process of Ab42.
To exploit the exceptional versatility of antibodies in molecular re-
cognition, we apply a recently developed method for the rational design
of single-domain antibodies to specifically bind disordered or otherwise
solvent-exposed linear epitopes within a target protein (38, 39). These
antibodies tend to preferentially bind the target epitopewhen the protein
is in the aggregated rather than in the monomeric conformation (38),
probably because of entropic effects due to the preorganization of the
epitope in the aggregated state. We thus generate here a small panel of
five human single-domain antibodies (Fig. 1) that are rationally designed
to bind Ab42; we call these antibodies DesAbs (“designed antibodies”).
Each DesAb in the panel is designed to target one epitope within the
peptide, with consecutive epitopes being selected to achieve close to full
coverage of the Ab42 sequence; we refer to this procedure as “antibody
scanning.” This procedure is related to the recently proposed epitope
mapping method (40) but differs from it because the antibodies that
we describe here are designed rationally, rather than being polyclonal
antibodies obtained with immunization techniques.
By combining highly reproducible fluorescence-based aggregation as-
says with a chemical kinetics framework for protein aggregation analysis1 of 11
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 (12, 41), we investigate the mechanism of inhibition of Ab42 aggregation
by the fiveDesAbs in the antibody scanning panel thatwe produced. This
approachdoes not require previous knowledge of the elusive structures of
the toxic species of Ab42 and could represent a highly sensitive method
for the quantitative detection of the effects of potential therapeutic mol-
ecules on the microscopic processes that underlie protein aggregation
(6, 20, 23). Furthermore, because of the low binding affinity that is often
observed in the interactions with disordered proteins such as Ab42,
conventional experimental methods, which have been largely developed
in the context of enzyme inhibition, remain challenging for the study of
the inhibition of protein aggregation (6). By contrast, the approach that
we adopt here is based on chemical kinetics and does not require tight
binding between a therapeutic molecule and an aggregation-prone pro-
tein in itsmonomeric conformation (6). Thus, even relatively low (micro-
molar) affinity binding to themonomeric forms of the target protein can
result in large effects on its aggregation behavior (42). These effects can
be achieved by a specific binding to aggregates (6) or by a type of binding
to monomers that perturbs the populations of their different conforma-
tions by decreasing those that are able to nucleate and aggregate (43).
Using this strategy, we identify two stable DesAbs of potential therapeu-
tic interest. The first,DesAb18–25, is designed to bind to the central region
of Ab42 (residues 18 to 25: VFFAEDVG), and the second,DesAb29–36, is
designed to bind to the C-terminal region of Ab42 (residues 29 to 36:
GAIIGLMV). We find that DesAb18–25 and DesAb29–36 are able to
selectively inhibit the primary and the surface-catalyzed secondary nucle-
ation of Ab42, respectively, and to consistently suppress the Ab42-
mediated toxicity in a Caenorhabditis elegans model.RESULTS AND DISCUSSION
Generation of an antibody panel against Ab42 using
antibody scanning
In this section, we describe an antibody scanning procedure for the ra-
pid in silico generation of antibody libraries.We applied this procedure
to Ab42 to obtain a pool of antibodies that are capable of binding dif-Aprile et al., Sci. Adv. 2017;3 : e1700488 21 June 2017ferent epitopes along the sequence of this peptide. From this pool, we
then identified those that are capable of selectively inhibiting specific
microscopic steps in the Ab42 aggregation process.
The method developed in this study is designed to generate a small
panel of antibodies that carry complementary-determining regions
(CDRs) rationally designed in silico to target different linear epitopes
that systematically cover the whole sequence of Ab42. Using this
method, we can replace library generation, biopanning, and ampli-
fication steps of standard in vitro technologies (29, 44) with a fast com-
putational procedure, focusing the experimental efforts exclusively on
functional screening. Specifically, for each target linear epitope along
the sequence of Ab42 (Fig. 1), we perform the following steps: (i) We
run the cascade method (38) of designing complementary peptides
binding to the target sequence; (ii) we select the most promising pep-
tide by using the scores from the cascade methods itself, which are re-
lated to the predicted binding (38), as well as the predicted solubility
calculated using the CamSolmethod (performing these two steps takes
only a few minutes on a standard laptop) (45); and (iii) we then graft
the selected complementary peptide onto the CDR3 of a human VH
(variable region of immunoglobulin heavy chain) domain antibody
scaffold, whichhas previously been shown to be stable andhighly tolerant
to the replacement of the CDR3 loop (46, 47). The designed peptides are
reported in Table 1.
Characterization of the binding of the DesAbs to Ab42
All the rationally designed DesAb variants were expressed in Esche-
richia coli and purified, as previously reported (fig. S1) (45). The five
different single-domain antibodies are namedDesAb3–9, DesAb13–19,
DesAb18–25, DesAb29–36, and DesAb36–42, where the subscript identifies
the region of the Ab42 sequence where the antibody is designed to
bind (Table 1). Circular dichroism (CD) spectroscopy revealed that
all DesAbs have a secondary structure content compatible with the
native conformation of a VH domain (Fig. 2A). Furthermore, no dif-
ferences were detected between the thermal stability of the DesAbs
and the original VH scaffold, as reported in the literature (Fig. 2, A
and B) (48). These results indicate that the grafting procedure that
we used does not produce significant changes in the structure and
stability of the original single-domain antibody.
Biolayer interferometry (BLI) (see Materials and Methods) using
streptavidin (SA) biosensor tips coated with N-terminal biotinylated
Ab42 was used to show that DesAb13–19, DesAb18–25, DesAb29–36, and
DesAb36–42 bind monomeric Ab42 with a Kd (dissociation constant)10 20 30
40
Fig. 1. Schematic representation of the DesAb panel against Ab42 gener-
ated using the antibody scanning method described in this work. The five
target epitopes, which scan the Ab42 sequence, are shown as green-framed rec-
tangular boxes, whereas the corresponding designed complementary peptides
grafted into the CD3 loop of the single-domain human antibody scaffold are
highlighted in green.Table 1. List of the different DesAbs used in this work.Antibody Grafted sequence Target sequenceDesAb3–9 HETLTLR (3)EFRHDSG(9)DesAb13–19 LSVIKEI (13)HHQKLVF(19)DesAb18–25 VFVGTEA (18)VFFAEDVG(25)DesAb29–36 GSMYKATV (29)GAIIGLMV(36)DesAb36–42 LGIKAEL (36)VGGVVIA(42)DesAb-F (38) FQEAVSG (70)VVTGVTA(76)
(a-synuclein)DesAb15–21 (38) FKLSVIT (15)QKLVFFA(21)2 of 11
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 ranging from 200 to 900 nM (Fig. 2C). As a control, we verified that a
related DesAb that carries a complementary peptide designed to bind
a-synuclein does not bind Ab42 in the same assay (Fig. 2C, gray
curve). In addition, we also show that the Ab42 DesAbs do not bind
a-synuclein (fig. S2). Likewise, in a previous study, we showed that
DesAbs designed to bind other amyloidogenic proteins, including
DesAb-F (Table 1), do not bind Ab42, illustrating the specificity of
these antibodies (38).
In the case of DesAb3–9, no significant binding signal was detected
in this BLI setup, most likely as a result of the close proximity of the
target epitope to the surface of the BLI biosensor tip. Therefore, for this
DesAb variant, the binding to Ab42 monomers was studied by means
of biotin-mediated affinity measurements (fig. S3). Specifically, we
incubated DesAb3–9 in the presence of different concentrations of
N-terminal biotinylated Ab42. The DesAb3–9/Ab42 complex formed
in solution was then removed by incubating the samples in an enzyme-
linked immunosorbent assay (ELISA) plate coatedwith SA. The amount
of DesAb3–9 left in solution was quantified by intrinsic fluorescence
measurements, and the corresponding fraction of bound DesAb3–9
was plotted as a function of the concentration of Ab42 monomers
in the sample (fig. S3). The affinity calculated in this manner (about
100 nM) was consistent with that of the other DesAbs reported above
(in the 200 to 900 nM range).
Furthermore, to verify whether or not theDesAbs interact with their
respective target regions of the Ab42 sequence, representative binding
measurements were carried out on DesAb18–25 and DesAb29–36 (fig.
S4). BLI measurements of DesAb18–25 and DesAb29–36 were recorded
in the presence of the corresponding chemically synthesized target epi-
topes Ab18–25 (Ac-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-NH2) and
Ab29–36 (Ac-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-NH2), respectively (seeAprile et al., Sci. Adv. 2017;3 : e1700488 21 June 2017Materials andMethods). These peptideswere the only ones among the
target epitopes in the Ab42 sequence (Fig. 1) that had sufficient solu-
bility under the experimental conditions that we used (see Materials
and Methods) for such analysis. Our analysis revealed that both anti-
bodies bind their respective target epitopes, as expected (fig. S4, A and
B). As a control of specificity, we performed a similar BLI experiment
by swapping the target epitope peptides (that is, we tested the binding
of DesAb18–25 with Ab29–36 and that of DesAb29–36 with Ab18–25) and,
under these conditions, we could not detect significant binding (fig. S4,
A and B). In the case of DesAb18–25, we further validated the binding
region on Ab42 by performing a competition assay in the presence of
DesAb-Ab (which we denote here as DesAb15–21), a DesAb previously
reported to bind the region Ab15–21 (38). To do this, we incubated a
fluorescently labeled variant of DesAb18–25, which retains a native-like
conformation as assessed by CD (fig. S4C), in the presence of an equi-
molar concentration of N-terminal biotinylated Ab42 and increasing
concentrations of DesAb15–21. The A647-DesAb18–25/N-terminal bioti-
nylated Ab42 complex was then isolated by means of an ELISA plate
coated with SA (see Materials and Methods), and the unbound A647-
DesAb18–25 was quantified by fluorescencemeasurements. As expected,
we found that DesAb15–21 is able to compete with DesAb18–25 for
the binding to Ab42 with a median inhibitory concentration (IC50) of
400 nM, which is in the same order of magnitude of the affinity of
DesAb18–25 for Ab.
We then investigated the ability of the DesAbs to bind aggregated
species ofAb42. To do so, we performed biotin-mediated affinitymea-
surements by using fibrils made of N-terminal biotinylated Ab42 (see
Fig. 2D and Materials and Methods). We found that some DesAbs
show a preferential binding toward fibrillar species. In particular,
the Kd values of binding of DesAb3–9, DesAb13–19, and DesAb18–25Fig. 2. Structural and functional characterization of the DesAbs. CD spectra (A) and CD thermal denaturation (B) of the DesAbs used in this work. WT, wild type.
(B) Denaturation data are reported as fraction of the folded protein (see Materials and Methods). (C) BLI measurements of the binding of the DesAbs to SA sensor chip
coated with monomeric biotinylated Ab42. Each curve was subtracted from a curve of binding of the corresponding DesAb to an uncoated sensor chip; the Kd values of
binding to monomeric Ab42 are reported. Given the proximity of the target peptide of DesAb3–9 to the biosensor surface, the affinity of DesAb3–9 for monomeric Ab42
was determined with biotin-mediated affinity measurements (fig. S3). n.a., not applicable. (D) Fibril binding experiments of the DesAbs; the Kd values of binding to
fibrillar Ab42 are reported. DesAb3–9, black; DesAb13–19, orange; DesAb18–25, blue; DesAb29–36, green; DesAb36–42, red; DesAb-F (a DesAb that targets a-synuclein), gray.
The gray dashed line in (B) indicates the Tm (≈73°C) of the original scaffold as reported in the literature (48).3 of 11
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 for Ab42 fibrils are 5, 200, and 500 nM, respectively, 100-, 5-, and 2-
fold better than the corresponding values for Ab42 monomers (Fig.
2D). The other antibodies bindAb42 fibrils with an affinity worse than
that for the monomers, in agreement with the recent report that the
central and the C-terminal regions of Ab42 are buried within the fi-
brils (Fig. 2D) (48, 49).
Inhibition by the DesAbs of different microscopic steps in
Ab42 aggregation
The formation of amyloid fibrils in vitro can be monitored using fluo-
rescent dyes, such as thioflavin T (ThT), which specifically interact with
the stacked b sheet structure of the amyloid fibrils (see Materials and
Methods). The development of a protocol to achieve highly reproduci-
ble kinetic data, together with the derivation of an analytical solution to
the coupled differential equations that govern amyloid growth (12), has
allowed the rates of themicroscopic processes that underpin the forma-
tion of the oligomeric species of Ab42 (Fig. 3A) to be extracted from
macroscopic measurements of the aggregation kinetics (13). In addi-
tion, this type of analysis has enabled the study of the mechanisms of
inhibition of protein aggregation by candidate therapeutic molecules
(6, 23). This approach consists of measuring ThT fluorescence–based
aggregation of Ab42 under reference conditions and monitoring the
changes in the aggregation kinetics upon systematic variations of the
concentration of a tested inhibitor. The perturbations in the reaction
profiles are then analyzed with a kinetic model to identify the mecha-
nisms of aggregation most affected by the interactions of the tested in-
hibitor with one or more of the species present in the system.
By applying this method, we measured by ThT fluorescence the
time evolution of the formation of Ab42 fibrils in the presence of vary-
ing concentrations of the different DesAbs.We observed a progressive
reduction in the overall rate of aggregation with increasing concentra-
tions of the DesAbs (Fig. 3B), which shows that all DesAbs designed to
bind Ab42 are effective in inhibiting its aggregation, even at substoi-
chiometric concentrations (as low as 1:32 antibody–to–Ab42 monomer
ratios). By contrast, the antibody DesAb-F (Table 1), which showed
a strong inhibitory effect on a-synuclein aggregation (38), does not
have any detectable effect on the aggregation of Ab42 (fig. S5). Because
DesAb-F differs from the antibodies designed to target Ab42 discussed
here only in the sequence of the complementary peptide grafted in the
CDR3 loop, these results indicate that the inhibitory effects observed on
the aggregation of Ab42 specifically originate from the computationally
designed peptides (Fig. 3B).
To identify the microscopic processes involved in the aggregation
of Ab42 that are most affected by the interaction with each antibody,
we determined the changes in the global parameters k+kn and k+k2
(where k+, kn, and k2 are the elongation, primary, and secondary rate
constants, respectively) by fitting the aggregation curves with the
integrated kinetic laws described above (fig. S6) (6). In addition, it is
particularly important to evaluate the perturbations in the individual
microscopic rate constants k+, kn, and k2. This information is relevant
in the light of the observation that the failure in clinical trials targeting
Ab aggregation may have resulted from a general and nonspecific in-
hibition of the aggregation process, potentially leading to the suppres-
sion of the formation of high–molecular weight aggregates at the
expenses of an increased number of small toxic oligomers (6). To evaluate
the changes in the individual microscopic processes, we complemented
the kinetic data under unseeded conditions by testing the effect of the
DesAbs in an assay that specifically probes the elongation of Ab42
fibrils (Fig. 3C). For this purpose, the DesAbs were introduced in aAprile et al., Sci. Adv. 2017;3 : e1700488 21 June 2017reaction mixture containing 2 mM monomeric Ab42 supplemented
with 0.2 mM preformed fibrils. At this high concentration of fibrils,
primary and secondary nucleation events are negligible, and only
elongation reactions contribute to the increase in the fibrillar mass.
We found that, at a 1:1 antibody–to–Ab42 monomer ratio, DesAb3–9
and DesAb29–36 do not have any significant effect on Ab42 aggregation
kinetics, indicating that they are unable to interfere with the elongation
of existing Ab42 fibrils. Instead, the antibodies DesAb13–19, DesAb18–25,
and DesAb36–42 show a strong effect on the seeded aggregation ki-
netics (Fig. 3C). After measuring the changes in k+ from the seeded
experiments, by considering the decreases in k+k2 and k+kn evaluated
from unseeded aggregations, we were in the position to determine the
decreases in the single microscopic rate constant for each DesAb (see
Materials and Methods). We found that, in the presence of the single-
domainantibodies raised against theN-terminal regionofAb42 (DesAb3–9
and DesAb13–19), both primary and secondary nucleation rate con-
stants were changed by up to two orders ofmagnitude (Fig. 3D). These
findings are consistent with a recent report that shows that themanip-
ulation of the N terminus of Ab42 affects all the microscopic steps in
the aggregation process of this peptide (50). However, DesAb18–25,
which targets the central region of Ab42, mainly affects kn, which
again decreases by two orders of magnitude, whereas k2 decreases
by only about 10-fold (Fig. 3D and Table 2). The two antibodies
designed to target C-terminal epitopes (DesAb29–36 and DesAb36–42),
by contrast, show a preferential inhibition of k2, which decreases by
about two orders of magnitude, whereas kn remains almost unaffected
(Fig. 3D and Table 2).
To determine how the reduction of the rate constants of the differ-
ent microscopic steps affects the formation of Ab42 oligomers, we es-
timated the change of the on-pathway oligomeric populations in the
presence of the different DesAbs by using the rate constants derived
from the kinetic analysis (Fig. 3E). We found that the antibodies with a
strong effect on secondary nucleation were the most effective in
inhibiting the formation of these oligomers. In particular, DesAb29–36,
which predominantly affects secondary nucleation, was the antibody
with the strongest effect by decreasing the number of oligomers by
97%. Strikingly, this decrease is larger than that (90%) caused by
DesAb13–19, which has a much more pronounced effect on the overall
aggregation process reported by the ThT measurements. By contrast,
the decrease (36%) caused by DesAb36–42 is much lower than that of
DesAb29–36, despite the fact that the overall unseeded aggregation
curves look very similar for these two antibodies. These results show
how the kinetic analysis used here makes it possible to extract very
important—but often hidden—information on on-pathway oligomer-
ic species from macroscopic measurements. Together, these results
show that the antibody scanning strategy introduced here is effective
for the rapid identification of antibodies that are capable of targeting
specific microscopic steps in protein aggregation, without the need for
any a priori knowledge about the regions of the peptide or protein that
are most important for the self-assembly process.
Rescue by DesAb18–25 and DesAb29–36 of Ab42-mediated
dysfunction in C. elegans
As previously discussed, effective therapeutic strategies against AD
that focus on inhibiting Ab42 aggregation are likely to require the
targeting of specific nucleation processes, instead of simply suppres-
sing the formation of high–molecular weight aggregates (6). In the
previous section, we have shown that DesAb18–25 and DesAb29–36
have specific effects on the primary and the secondary nucleation4 of 11
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 rate constants, respectively. In particular, DesAb29–36 almost exclu-
sively affects the secondary nucleation rate, without any detectable
effect on the elongation of existing Ab42 fibrils (Fig. 3, C and D, and
Table 2).Aprile et al., Sci. Adv. 2017;3 : e1700488 21 June 2017To test the effects of the antibodies on the formation of Ab42 ag-
gregates in vivo, we used a C. elegans model of Ab42-mediated dys-
function, denoted GMC101, in which human Ab42 is expressed in
body wall muscle cells where it forms aggregates and results in severeFig. 3. The antibody scanningmethod produces antibodies that affect different microscopic steps in Ab42 aggregation. (A) Model of aggregation of Ab42 showing the
primary (red arrow) and the secondary (blue arrow) nucleation of the oligomers and the elongation of the fibrils (black arrow). (B) Solutions containing 2 mM Ab42 were
incubated in the presence of increasing (blue to green) Ab42 monomer equivalents of the DesAbs (serial dilutions starting from 1 mMDesAb concentration; see fig. S5); each
antibody targets a specific epitope within the sequence of Ab42 (Fig. 1) and inhibits the aggregation of the peptide in a characteristic manner. Continuous lines represent the
fits of the data using the integrated rate law for Ab42 aggregation (seeMaterials andMethods). (C) Seeded aggregation of Ab42 in the presence of 10%preformed fibrils with a
0:1 (blue) or 1:1 (green) antibody–to–Ab42monomer ratio. a.u., arbitrary units. (D) Bar plot showing the inhibition strengthof theDesAbs (which is defined as kAb42/kAb42+DesAb)
on k+ (black), kn (red), and k2 (blue) rate constants, derived from (B), (C), and fig. S5. The fold change in the presenceof the antibodies of eachof the rate constants is indicatedon
the top of the corresponding bar. (E) Relative number of oligomers generated during the aggregation reaction with or without a 1:2 antibody–to–Ab42 monomer ratio.5 of 11
SC I ENCE ADVANCES | R E S EARCH ART I C L E
 o
n
 June 29, 2017
http://advances.sciencem
ag.org/
D
ow
nloaded from
 age-progressive paralysis (51). Specifically, the effects of the adminis-
tration of the antibodies observed using this worm model were com-
pared to those observed in control worms (N2, wild type), which do not
express Ab42 (see Materials and Methods). To analyze the effects of
the two DesAbs on the toxicity of Ab42 in worms, we developed a
protocol for the transduction of native proteins into living worms
based on a commercially available reagent for lipid-mediated trans-
duction of macromolecules into mammalian cells (see Materials and
Methods). The effectiveness of the procedure was first tested by
administering 20 mM mCherry fluorescent protein encapsulated into
the lipid vesicles of the reagent into control worms as suspensions in a
MES buffer solution (see Materials andMethods). A confocal micros-
copy analysis performed after 4 hours of incubation revealed the pres-
ence of the specific fluorescence of mCherry (fig. S7), thus indicating
that mCherry is delivered effectively into the cells and has retained the
native conformation.
We then performed the same protocol using lipid vesicles intowhich
each of the two DesAbs was encapsulated at a concentration of 20 mM
and measured the frequency and amplitude of the body bends, which
are indicative of the state of themuscle cells and of the overall viability of
theworms (Fig. 4).We administered the antibodies at different stages of
adulthood to test their effects at different phases of the aggregation pro-
cess in vivo. The expectation from the in vitro results is that the antibody
that inhibits primary nucleation should bemost effective in an early ad-
ministration, whereas that inhibiting secondary nucleation should be
most effective in a late administration. Therefore, in one experiment,
the DesAbs were administered at days 1 and 3, whereas in another ex-
periment, the DesAbs were administered only at day 6. Phenotypic dif-
ferences were screened at day 7 in both cases. To correct for secondary
effects of the treatments on the fitness of the worms (as, for example, an
improvement ofmotility as a consequence of themetabolism of the lipid
molecules of the vesicles), Ab42 and control worms were treated with
empty vesicles and comparedwithworms treatedwith the samenumbers
of antibody-filled vesicles.
In the presence of both antibodies, the frequency of the body bends,
their amplitude, and the viability of Ab42 worms increase significantly
(Fig. 4 and fig. S8; movies S1 to S7 illustrate the effects of the treatment).
In particular, the antibodyDesAb29–36 that inhibits secondary nucleation
shows a substantial effect on all the three measured parameters when
administered at day 6 andproduces an almost full recovery of the pathol-
ogical phenotype (Fig. 4). The administration at day 6 of DesAb18–25,
which inhibits primary nucleation in vitro, also induces an improvement
of the phenotype, but to a significantly lower level than that observed for
DesAb29–36. By contrast, the effect of DesAb18–25 is much larger uponAprile et al., Sci. Adv. 2017;3 : e1700488 21 June 2017early administration at days 1 and 3, compared to late administration, in
line with the in vitro findings that a primary nucleation inhibitor loses
its efficacy once a sizeable amount of aggregates have formed. As a fur-
ther control, following the administration at days 1 and 3, we also
screened the viability of the worms at day 4 and obtained very similar
results to those from the screening at day 7, as discussed above (fig. S9).
Notably, no significant effects on the measured phenotypic parameters
were observed following the administration of theDesAbs to the control
worms (fig. S10) or to a wormmodel of a-synuclein–mediated toxicity
(OW40) (fig. S11A). In addition, no significant effects were detected
upon the administration of DesAb-F to the Ab42 worms (fig. S11B).
Together, these results illustrate the efficacy of our strategy. Finally, fluo-
rescence imaging using the amyloid-specific probe NIAD-4 (see
Materials andMethods) shows that the treatments using theDesAbshave
a direct effect on the amount of Ab42 aggregates in the worms (fig. S12).
Together, these results show that the administration of both anti-
bodies has a beneficial effect in aC. elegansmodel ofAb42-mediated dys-
function. Furthermore, the antibody-specific inhibition of Ab42 toxicity
observed in vivo is consistent with the different effects that the two anti-
bodies haveon themicroscopicprocesses invitro. Inparticular,DesAb18–25
preferentially affects primary nucleation in vitro, which is the critical pro-
cess of formation of oligomers at early stages of the aggregation process
of Ab42 (13). In agreement with this observation, we have found that
DesAb18–25 is most effective when administered at the onset of the disease
when theworms are still relatively young. Similarly, DesAb29–36 is a potent
inhibitor of secondary nucleation in vitro and suppresses the effects of
Ab42 aggregationmost effectively in vivo when administered at late stages
of the worm maturation. This result is in agreement with the in vitro ob-
servation that secondarynucleationbecomes thepredominantmechanism
of generationofAb42oligomers once a criticalmass of aggregates has been
formed (13), which happens later on in the maturation of the worms.CONCLUSIONS
We have described an antibody scanning strategy for the rapid produc-
tion of small antibody librarieswith full coverage of given target proteins.
Because this strategy is based on rational design, the resulting libraries
can be of very small size, which makes them particularly amenable to
quantitative screening procedures.Wehave illustrated the efficacy of this
approach by generating a pool of antibodies designed to scan the
sequence of Ab42 and then by using kinetic methods to test the ability
of these antibodies to inhibit specific microscopic steps in Ab42 aggre-
gation. This analysis has revealed that all DesAbs have significant effects
on Ab42 aggregation in vitro, and it has allowed us to identify two anti-
bodies that target, respectively, the primary and secondary nucleation of
the aggregation process with high selectivity. We have then confirmed
that these in vitro results are fully consistent with the effects of the two
antibodies in vivo using a C. elegansmodel of Ab42-mediated toxicity.
Aparticularly important aspectof the antibody scanningapproach that
we have presented is that to design the antibody panel and to identify the
most effective antibodies, we did not exploit any a priori knowledge about
the structures of the aggregates or about the sequence regions that aremost
important in determining their formation. The only information that we
have used concerned solely the amino acid sequence of Ab42. Although
we have illustrated here the antibody scanning technique by primarily ad-
dressingkinetic questions, namely, to identify antibodies that are capable of
interfering with specific microscopic steps in the aggregation of Ab42, in
principle it should also be possible to use them to obtain insights into the
structural properties ofAb42monomers, oligomers, and fibrils.However,Table 2. Changes in themicroscopic rate constants in Ab42 aggregation
in thepresenceof the differentDesAbs used in thiswork (elongation,k+;
primary nucleation, kn; and secondary nucleation, k2).Antibody k+ knk+ k2k+ kn k2DesAb3–9 1.2 205.1 68.7 173.8 58.2DesAb13–19 8.0 1210.9 760.9 150.1 94.8DesAb18–25 3.9 723.4 3.2 183.6 0.8DesAb29–36 1.5 35.1 206.2 23.4 137.4DesAb36–42 9.9 7.4 127 0.8 12.96 of 11
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 these structural studies are complicated by the possibility that the confor-
mational properties of Ab42 may be affected by the binding of the anti-
bodies. For example, a specific insight that we can already obtain from the
present results is that DesAb29–36, which inhibits secondary nucleation, is
likely to do so by interacting with secondary oligomers, rather than with
the fibril surfaces, because its epitope is not exposed in the two recently
reported structures of Ab42 fibrils (48, 49).
We anticipate that the strategy that we have introducedmay find ap-
plications for the effective rational identification of a wide range of can-
didate protein therapeutics against neurodegenerative diseases. More
generally, we may also expect that the antibody scanning method will
help the functional characterization of proteins by monitoring the
changes in their activity when specific regions of their sequences are
bound to the corresponding antibodies.MATERIALS AND METHODS
Design of the antibodies
We summarize here the computational method that we have developed
for the identification of complementary peptides that bind to specificAprile et al., Sci. Adv. 2017;3 : e1700488 21 June 2017linear epitopes in target proteins of interest, which we have grafted onto
the CDR loops of domain antibodies. A detailed description of the
method is provided by Sormanni et al. (38), together with additional ex-
perimental validation. The complementary peptide design procedure
consisted of two steps. First, given a target linear epitope, we collected
from the Protein Data Bank (PDB) all protein fragments that face in a
b strand any subsequence of at least three residues in which the target
epitope can be fragmented. Second, complementary peptides predicted
to bind the target epitopewere built bymerging together these fragments
using a “cascade method.” In essence, this cascade method started from
one of these fragments and extended it to the length of the target epitope
by linking it to some of the others. Fragments were linked using three
rules: (i) Fragments can be joined together only if found in b strands of
the same type (that is, parallel or antiparallel), (ii) all fragments making
up a complementary peptide must partly overlap with their neighboring
fragments, and (iii) the overlapping regionsmust be identical both in the
sequence and in the backbone hydrogen-bond pattern that is extracted
from the b strand where each fragment is found.
Because the identification of the complementary peptides is based
on the analysis of amino acid sequences facing each other in b strandsFig. 4. Effects of DesAb18–25 and DesAb29–36 in a C. elegans model of Ab42-mediated toxicity. (A) Experimental design for the investigation of the effects of the
two selected DesAbs in the C. elegans strain GMC101 (the Ab42 worm model) compared with strain N2 (the control worm model). The pathological phenotype is
induced in the worms by increasing their temperature of incubation from 20° to 24°C, which induces Ab42 aggregation. A pictorial representation of the populations of
monomers (light blue), oligomers formed by primary (blue) and secondary (green) nucleations, and fibrils (maroon) at the different stages (in days) of adulthood of the
worms is given to illustrate the aggregation process. (B) Phenotypic fingerprints, which consider speed, body bends per minute (BPM), and fraction not paralyzed or the
worms, of Ab42 worms (C. elegans GMC101; yellow) and control worms (C. elegans N2, WT; gray) treated with empty lipid vesicles and after the administration of
DesAb29–36 (green) and DesAb18–25 (blue), screened at day 7 of adulthood. DesAbs were administered starting from a 20 mM concentration (see Materials and Methods)
at days 1 and 3 (left) or at day 6 (right). The fingerprints show one representative of three biological replicates that showed similar results. The thickness of the lines
represents SEM. The bar plots report the total fitness (see Materials and Methods). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001 (relative to untreated
worms).7 of 11
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 in the PDB, the interaction with the target sequence is already shown
to be viable in a biological context. In addition, given this design
strategy, the resulting complementary peptides are expected to bind
the target epitope by enforcing a b strand–like conformation. There-
fore, these complementary peptides will be particularly effective in
binding to solvent-exposed regions of protein sequences that do not
form persistent hydrogen bonds with other parts of the protein mol-
ecule, such as in the case of disordered regions (38).
Protein expression and purification
The various complementary peptides were grafted into the CDR3 loop
of theDesAb scaffold bymeans ofmutagenic polymerase chain reaction
with phosphorylated oligonucleotides (38). The different DesAb con-
structs were then expressed and purified using pRSET-B vector in
E. coli Rosetta-gami 2 (DE3) (MerckMillipore), as previously described
(38). Cells were grown for 15 hours at 30°C using Overnight Express
Instant TB Medium (Merck Millipore) supplemented with ampicillin
(100 mg/ml). Cells were harvested by centrifugation; resuspended in 8 mM
Na2HPO4, 15 mM KH2PO4, 137 mM NaCl, and 3 mM KCl (pH 7.3)
[phosphate-buffered saline (PBS)] with the addition of one EDTA-Free
Complete Protease Inhibitor Cocktail Tablet (Roche) per 500 ml of cell
growth; and lysed using sonication. Cell debris was removed using centrif-
ugation at 15,000 rpm (JA-20 rotor, Beckman Coulter). The cleared lysate
was loaded onto a Ni2+-NTA Superflow column (Qiagen), previously
equilibrated with PBS containing 10 mM imidazole. After washing
with PBS containing 40 mM imidazole, the His-tagged DesAbs were
elutedwith PBS containing 200mM imidazole and dialyzed extensive-
ly against PBS. For all the protein variants used in this study, protein
concentrationwas determined by absorbancemeasurement at 280 nm
using theoretical extinction coefficients calculatedwith ExPASyProtParam
(52). Ab42 peptides were expressed in E. coli BL21 (DE3) Gold Strain
(Agilent Technologies) andpurified, as described previously (13). Aliquots
of purified Ab42 were lyophilized and stored at −80°C.
Circular dichroism
Far-ultraviolet (UV) CD spectra of theDesAbs were recorded using a
Jasco J-810 spectropolarimeter equipped with a Peltier holder, using
a 0.1-cm-pathlength cuvette. Samples contained 10 mM protein in
PBS. The far-UV CD spectra of all DesAbs were recorded from
200 to 250 nm at 20°C, and the spectrum of the buffer was system-
atically subtracted from the spectra of all DesAbs.
The structural stability of the DesAbs was analyzed by monitoring
theCDsignal at 207 nm from20° to 98°C at a rate of 0.5°Cmin−1. Data
points were acquired every 0.1°C with a bandwidth of 1 nm. Analysis
of the thermal unfolding curves was performed, assuming a two-state
unfolding model.
BLI measurements
The binding between the various DesAbs and monomeric Ab42 was
assayed by means of BLI experiments with a ForteBio Octet RED96
(Pall ForteBio LLC). Specifically, SA biosensor tips were coated with
monomeric N-terminal biotinylated Ab42 (AnaSpec) by incubation
in peptide solution (15 mg/ml) for 10 s and then blocked in PBS, 0.1%
bovine serum albumin (BSA), and 0.05% Tween 20 for 15 min.
The binding between the immobilized Ab42 peptide and the
DesAbs was monitored in the presence of 5 mM antibody solution in
PBS, 0.1% BSA, and 0.02% Tween 20 for 250 s. Then, the dissociation
of the DesAbs was monitored in PBS, 0.1% BSA, and 0.05% Tween
20 for 250 s.Aprile et al., Sci. Adv. 2017;3 : e1700488 21 June 2017The binding of DesAb18–25 and DesAb29–36 to the target peptides
(ChinaPeptides) Ab18–25 (Ac-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-
NH2) and Ab29–36 (Ac-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-NH2), re-
spectively, was analyzed as follows: Ni-NTA biosensor tips were
coated with DesAb18–25 or DesAb29–36 by incubation in an antibody
solution (15 mg/ml) for 10 s.DesAb18–25 orDesAb29–36 association and
dissociation with 6 and 20 mM peptide, respectively, were monitored
in PBS, 1% BSA, and 0.05% Tween 20. As a control of specificity, the
binding of DesAb18–25 to Ab29–36 and that of DesAb29–36 to Ab18–25
were also tested.
The binding of the different DesAbs to monomeric a-synuclein
was analyzed as follows: Ni-NTA biosensor tips were coated with the
DesAbs by incubation in an antibody solution (15 mg/ml) for 10 s.
The association and dissociation between the immobilized DesAbs
and 20 mM a-synuclein were monitored for 300 s in PBS, 1% BSA,
and 0.05% Tween 20. In all cases, the binding curves were corrected
by subtracting nonspecific binding to the biosensor tips.
Biotin-mediated affinity measurements and fluorescence
competition assay
Samples containing 2 mM DesAbs and increasing concentration of
monomeric or fibrillar N-terminal biotinylated Ab42 (0, 0.1, 0.2, 0.4,
0.8, 1.6, 3.2, 6.4, and 12.8 mM) were incubated overnight at room tem-
perature. The DesAb/biotinylated Ab42 complex was then isolated
from the solution by incubating the 1:1000 diluted samples in an
ELISA plate (Thermo Fisher Scientific), which was previously coated
with 50 ng of Alexa 488–streptavidin (Thermo Fisher Scientific) and
blocked with 10% (w/v) BSA in PBS (BSA/PBS) overnight at 4°C,
following six times washing with PBS. The uniformity of the coating
reaction was verified by measuring the fluorescence of Alexa 488 in
each well using a CLARIOstar plate reader (BMG Labtech) (fig. S3).
Samples were then removed from the plate, and the DesAb left in
the solution was quantified by measuring the maximal intrinsic flu-
orescence between 300 and 400 nm (≈350 nm) upon excitation at
285 nm. The concentrations of DesAbs and Ab42 and the excitation
and the emission wavelengths used for the analysis were selected to
attenuate possible artifacts due to the high sensitivity of tryptophans
to small environmental changes in general and to minimize the con-
tribution of the only tyrosine of Ab42 to the intrinsic fluorescence
measurements (fig. S13). The decrease in fluorescence signal was
plotted as a function of Ab42 concentration and analyzed assuming
single-site binding using
DF ¼ DFmaxQL
¼ DFmax
2LT
ðPT þ LT þ KdÞ þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðPT þ LT þ KdÞ2 4PTLT
q 
where QL is the fraction of bound ligand, DF is the decrease in fluo-
rescence intensity observed at a given concentration of DesAb,DFmax
is the maximal decrease in fluorescence at saturation, LT and PT are
the total ligand and protein concentrations, respectively, and Kd is
the apparent dissociation constant of the complex. The fraction of
bound ligand was plotted as a function of protein concentration to
compare affinities between the different DesAbs.
The fluorescence competition assaybetweenDesAb18–25 andDesAb15–21
[referred to as DesAb-Ab by Sormanni et al. (38)] was performed as
follows. DesAb18–25 was labeled with fluorophore Alexa 647 using the
Alexa Fluor 647 Antibody Labeling Kit (Thermo Fisher Scientific)8 of 11
SC I ENCE ADVANCES | R E S EARCH ART I C L E
 o
n
 June 29, 2017
http://advances.sciencem
ag.org/
D
ow
nloaded from
 according to themanufacturer’s instructions. The conformation of the an-
tibody after the labeling reaction was assessed by CD using the same
protocol described in the “Circular dichroism” section (fig. S4C). Samples
containing 50 nMmonomeric N-terminal biotinylated Ab42 and 50 nM
Alexa 647–DesAb18–25 were incubated in the presence of increasing con-
centrations ofDesAb15–21 (0, 100, 200, 400, 800, and 1600nM) for 2 hours
at room temperature. The Alexa 647–DesAb18–25/biotinylated Ab42
complex was then isolated from the solution by incubating the samples
in an ELISA plate (Thermo Fisher Scientific) previously coated with
50 ng per well of Alexa 488–streptavidin (Thermo Fisher Scientific), as de-
scribed above. After incubation, the samples were transferred in a second
plate and the unbound Alexa 647–DesAb18–25 left in the solution was
quantified by measuring the fluorescence of Alexa 647 of each well using
a CLARIOstar plate reader (BMG Labtech). The same procedure was
applied for samples in which biotinylated Ab42 was not present and the
fluorescence value obtained from these samples was assumed to be the
fluorescence of 100% unbound Alexa 647–DesAb18–25. The fraction of
bound Alexa 647–DesAb18–25 at each concentration of DesAb15–21 was
then determined using
QL ¼ 1 FBAbFBAb
whereQL is the fraction of bound ligand (Alexa 647–DesAb18–25), FBAb
is the fluorescence intensity of Alexa 647–DesAb18–25 of samples
containing biotinylated Ab42, and F−BAb is the fluorescence intensity
of Alexa 647–DesAb18–25 of samples in which biotinylated Ab42 was
not added, at a given concentration of DesAb15–21. The data were then
fitted using an inhibition model with variable slope using the program
Prism 6 (GraphPad Software).
Aggregation assays
The lyophilized Ab42 peptide was dissolved in 6 M urea (pH 8.5) and
incubated for 30 min at room temperature. This protein solution was
then subjected to gel filtration using a Superdex 75 10/300 GL column
(GEHealthcare), and the peak corresponding to themonomeric Ab42
peptide was collected in low-binding test tubes (Corning) on ice (13).
Monomeric Ab42 peptides were used to prepare solutions at a pro-
tein concentration of 2 mMin the presence of increasing amounts of the
specified DesAb variant in 20 mM sodium phosphate buffer (pH 8),
200 mM EDTA, and 0.02% NaN3, supplemented with 6 mM ThT
(13). Seeded experiments were performed in the presence of 10% pre-
formed fibrils (23) with a 0:1 or 1:1 antibody–to–Ab42monomer ratio.
Each samplewas thenpipetted intomultiple wells of a 96-well half-area
plate of black polystyrene with a clear bottom and polyethylene glycol
coating (Corning) (90 ml per well). Plates were sealed to prevent evap-
oration. Aggregation assays were performed at 37°C under quiescent
conditions using a CLARIOstar plate reader (BMG Labtech). The ThT
fluorescence was measured through the bottom of the plate every min-
ute with an excitation filter of 440 nm and an emission filter of 480 nm.
Kinetic analysis
The time evolution of the total fibril mass concentration,M(t), in the
absence of seeds is described by the following integrated rate law
MðtÞ
Mð∞Þ ¼ 1
Bþ þ Cþ
Bþ þ Cþekt
B þ Cþekt
B þ Cþ
  k2∞
k~k∞
ek∞tAprile et al., Sci. Adv. 2017;3 : e1700488 21 June 2017where the kinetic parameters B±, C±, k, k∞, and ~k∞ are described in
detail in the study of Cohen et al. (20) and are functions of the two
combinations of the microscopic rate constants k+k2 and knk2, where
kn, k+, and k2 are the primary nucleation, elongation, and secondary
nucleation rate constants, respectively.
The DesAbs can perturb the aggregation process by inhibiting
one or more of the individual microscopic reactions.We can identify
the microscopic events that are inhibited by the DesAbs by applying
the above equation to describe the macroscopic aggregation profiles
shown in Fig. 3 and comparing the set of microscopic rate constants
k+k2 and knk2 required to describe the time evolution of the fibril
formation in the absence and presence of antibody.
The decrease in the parameter k+ in the presence of DesAbs was
calculated from the seeded experiments. On this purpose, we evaluated
the rate of the formation of fibrillar aggregates within the first 10% of
monomer conversion, r = 2k+P0m, where P0 is the number of seeds intro-
duced in the system andm is the initial monomer concentration. The re-
lative decrease in the apparent rate constant k+ was evaluated by dividing
the rate in thepresenceofDesAbswith thevalue calculated in their absence.
Finally, the decreases in kn and k2 (Table 2) were calculated by dividing the
decreases in k+k2 and k+kn (Table 2) obtained under unseeded conditions
by the decrease in k+ derived from the seeded aggregation profiles.
The perturbation of the different microscopic reaction rates has
markedly different effects on the generation of low–molecular weight
oligomeric species. To illustrate this behavior, we calculated the time
evolution of the rate of generation of new fibrils (via on-pathway oli-
gomers) from monomers according to the nucleation rate rn(t) given by
rn(t) = knm(t)
nc + k2M(t)m(t)
n2. Because a negligible amount of oligomers
was detectable in the system at the end of the reaction, the total number
of fibrils present at the end of the processwas indicative of the total num-
ber of on-pathway oligomers generated during the reaction. This value
was calculated by integrating the nucleation rate rn(t) over the reaction.
Strains of C. elegans
The following strains were used in the present work to assess the effect
of the antibodies on the toxicity of Ab42 aggregates:
(1) GMC101; genotype dvIs100 [unc-54p::A-beta-1-42::unc-54 3′-
UTR + mtl-2p::GFP]; mtl-2p::GFP constitutively expresses the green
fluorescent protein (GFP) in intestinal cells; unc-54p::A-beta-1-42
expresses the human full-length Ab42 peptide in body wall muscle
cells. Shifting L4 or young adult animals from 20° to 25°C promotes
Ab42 aggregation and causes the paralysis of the worms (51).
(2) N2, wild-type C. elegans var Bristol, in this work referred to as
control worms or wild-type worms. Generation time is about 3 days.
Brood size is about 350 [isolated frommushroomcompost near Bristol,
England by L. N. Staniland (53)].
(3) OW40 [strain expressing yellow fluorescent protein (YFP)–a-
synuclein] genotype zgIs15 [P(unc-54)::a-syn::YFP]IV. In OW40,
a-synuclein fused to YFP relocates to inclusions, which are visible as
early as day 2 of adulthood and increase in number and size during the
aging of the animals (54).
Propagation conditions of C. elegans
C. elegans worms were propagated using standard conditions (53).
Briefly, the animals were synchronized by hypochlorite bleaching,
hatched overnight in M9 [KH2PO4 (3 g/liter), Na2HPO4 (6 g/liter),
NaCl (5 g/liter), and 1 mMMgSO4] buffer, and subsequently cultured
at 20°C on nematode growth medium (NGM) [1 mM CaCl2, 1 mM
MgSO4, cholesterol (5 mg/ml), 250 mM KH2PO4 (pH 6), Bacto agar9 of 11
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 (17 g/liter), NaCl (3 g/liter), and casein (7.5 g/liter)] plates seeded with
the E. coli strain OP50. Saturated cultures of OP50 were grown by
inoculating 50 ml of LB medium [Bacto tryptone (10 g/liter), NaCl
(10 g/liter), and Bacto yeast extract (5 g/liter)] withOP50 and incubating
the culture for 16 hours at 37°C. NGM plates were seeded with bacteria
by adding 350 ml of saturated OP50 to each plate and leaving the plates
at 20°C for 2 to 3 days.On day 3 after synchronization, the animals were
placed on NGM plates containing 5-fluoro-2′deoxyuridine (FUDR)
(75 mM, unless stated otherwise) to inhibit the growth of offspring.
Antibody transduction protocol
About 500C. eleganswormswere incubated overnight inM9with 20 mM
of m-cherry protein (ABE3463, Bioscience Lifesciences) and 40 mM of
PULSin (PolyPlus-transfection SA) in a final volume of 1 ml. Motility
or imaging procedures were carried out 12 hours after transduction.
All experimentswere carried out in triplicate, and one experiment that
is representative of the three measured is shown.
Automated motility assay on agar plates and imaging of
the aggregates
All C. elegans populations were cultured at 20°C and developmentally
synchronized from a 4-hour egg lay. At 64 to 72 hours after egg lay
(time zero), individuals were shifted to 24°C and transferred to FUDR
plates and body movements were assessed over the times indicated. At
different ages, specifically at days 1 and 3 [administration protocol
1 (AP1)] or at day 6 (AP2), the animals were washed off the plates
and incubated with 20 mM DesAbs overnight in M9 buffer. At day 7,
the worms were spread over an OP50 unseeded 9-cm plate, and their
movements were recorded at 30 fps (frames per second) using a novel
microscopic setup for 30 s or 1 min. Up to 1000 animals were counted
in each experiment, unless stated otherwise. Videos were analyzed using
a custom-made tracking code. In the case of the AD1, the worms were
also screened at day 4 to assess whether the antibodies lose efficacy at day
7 as a consequence of degradation, which may be significant in the
case of experiments involving a long period between administration
and screening. The total fitness was calculated by summing the mo-
bility, speed, and viability of the worms. Fingerprint and total fitness
values were normalized using the values of the control worms.
To visualize the amount of aggregates in the worms, live transgenic
worms at day 9 of adulthood were incubated with 1 mMNIAD-4 (0.1%
dimethyl sulfoxide inM9buffer) for 4 hours at room temperature. After
staining, animalswereallowed to recoveronNGMplates for about24hours
(day 10 of adulthood) to allowdestaining via normalmetabolism. Stained
animals were mounted on 2% agarose pads containing 40 mMNaN3 as
anesthetic on glass microscope slides for imaging. Images were captured
using a Zeiss Axio Observer D1 fluorescence microscope (Carl Zeiss
Microscopy GmbH) with a 20× objective and a 49004 ET-CY3/TRITC
filter (Chroma Technology Corp.). Fluorescence intensity was calculated
using ImageJ software (National Institutes of Health) and then normalized
as the corrected total cell fluorescence.Only thehead regionwas considered
because of the high background signal in the guts. All experiments were
carried out in triplicate, and the data from one representative experiment
are shown. Statistical significance was determined using t tests.SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/3/6/e1700488/DC1
fig. S1. Purified DesAbs used in this study.
fig. S2. BLI analysis of the interaction of different DesAbs with monomeric a-synuclein.Aprile et al., Sci. Adv. 2017;3 : e1700488 21 June 2017fig. S3. Biotin-mediated affinity measurement of DesAb3–9 binding to monomeric Ab42 and
setup of the experimental conditions.
fig. S4. DesAb binding specificity assessment and interaction of DesAb18–25 and DesAb29–36
with the respective target peptides.
fig. S5. A DesAb designed to target a-synuclein does not inhibit Ab42 aggregation.
fig. S6. Effect of the DesAbs on the global parameters k+kn and k+k2 of Ab42 aggregation.
fig. S7. Transduction of the fluorescent protein mCherry into wild-type worms.
fig. S8. Effects of DesAb18–25 and DesAb29–36 treatments on the C. elegans worms.
fig. S9. Fingerprints of the Ab42 worms screened at day 4 of adulthood.
fig. S10. Effects of DesAb18–25 and DesAb29–36 treatments on wild-type control worms.
fig. S11. Analysis on the specificity of the treatment with the DesAbs in C. elegans.
fig. S12. Effects of DesAb18–25 and DesAb29–36 treatments on the aggregation of Ab42 in
C. elegans models.
fig. S13. Difference between the spectrum of DesAb18–25 and the background.
movie S1. Representative video clip of the Ab42 C. elegans worms GMC101 at day 7 upon
treatment with empty vesicles at days 1 and 3 (AP1, early treatment).
movie S2. Representative video clip of the Ab42 C. elegans worms GMC101 at day 7 upon
treatment with empty vesicles at day 6 (AP2, late treatment).
movie S3. Representative video clip of the control C. elegans worms N2 at day 7 upon
treatment with empty vesicles at day 6 (AP2, late treatment).
movie S4. Representative video clip of the Ab42 C. elegans worms GMC101 at day 7 upon
treatment with DesAb18–25 at days 1 and 3 (AP1, early treatment).
movie S5. Representative video clip of the Ab42 C. elegans worms GMC101 at day 7 upon
treatment with DesAb29–36 at days 1 and 3 (AP1, early treatment).
movie S6. Representative video clip of the Ab42 C. elegans worms GMC101 at day 7 upon
treatment with DesAb18–25 at day 6 (AP2, late treatment).
movie S7. Representative video clip of the Ab42 C. elegans worms GMC101 at day 7 upon
treatment with DesAb29–36 at day 6 (AP2, late treatment).REFERENCES AND NOTES
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